Escolar Documentos
Profissional Documentos
Cultura Documentos
Therapy
Akhmad Edy Purwoko
Pharmacology & Toxicology Dept.
Faculty of Medicine and Medical Sciences
Muhammadiyah University of
Yogyakarta
01/10/17
The Problem
Irrational Prescribing Prevalent
Medical Education emphasises
diagnosis
Therapeutics, accurate
prescribing and communication
skills often neglected
Problem solving, intergration
and self-directed learning skils
often under-developed
Rational drug use requires
complex risk-benefit
assessment
Dramatically increased number
of drugs available
01/10/17
01/10/17
01/10/17
01/10/17
Example: patient 1
You sit in with a general practitioner and observe
the following case. A 52-year old taxi-driver
complains of a sore throat and cough which
started two weeks earlier with a cold. He has
stopped sneezing but still has a cough, especially
at night.
The patient is a heavy smoker who has often been
advised to stop. Further history and examination
reveal nothing special, apart from a throat
inflammation.
The doctor again advises the patient to stop
smoking, and writes a prescription for codeine
tablets 15 mg, 1 tablet 3 times daily for 3 days.
01/10/17
01/10/17
10
Selecting a P-drug
01/10/17
11
Introduction to P-drugs
As a doctor you may see 40 patients per day or more,
many of whom need treatment with a drug. How do
you manage to choose the right drug for each patient
in a relatively short time? By using P-drugs! P-drugs
are the drugs you have chosen to prescribe regularly,
and with which you have become familiar. They are
your priority choice for given indications.
The P-drug concept is more than just the name of a
pharmacological substance, it also includes the
dosage form, dosage schedule and duration of
treatment.
01/10/17
12
13
01/10/17
14
01/10/17
15
01/10/17
16
17
01/10/17
18
19
01/10/17
20
01/10/17
21
01/10/17
22
01/10/17
23
01/10/17
24
01/10/17
25
01/10/17
26
efficacy
safety
suitability
cost
Group 1
Group 2
Group 3
01/10/17
27
Choose a P-drug
Efficacy
safety
suitability
cost
Drug 1
Drug 2
Drug 3
Conclusion:
01/10/17
01/10/17
29
30
01/10/17
31
01/10/17
32
01/10/17
33
01/10/17
34
01/10/17
35
01/10/17
36
01/10/17
37
01/10/17
38
01/10/17
39
01/10/17
40
01/10/17
41
01/10/17
42
01/10/17
43
01/10/17
44
01/10/17
45
01/10/17
46
Summary
01/10/17
47
ContraindicationsInteraction
High risk groups.
Active substance, Drug form
Dose, Schedule
01/10/17
48